Letrozole in pediatric females for peripheral precocious puberty: a systematic review of efficacy and safety
Authors' conclusion
Letrozole demonstrates meaningful clinical benefits in girls with PPP, particularly regarding pubertal control and predicted adult height, accompanied by a favourable safety profile.
Study context
- Population
- Girls aged ≤18 years with peripheral precocious puberty, predominantly McCune-Albright syndrome
- Participants
- 151 participants22 observational studies
- Outcome
- Efficacy in PPP
Methodological detailsPRISMA 2020, narrative synthesis (SWiM), Risk of bias assessed with JBI checklists and Murad tool
- PRISMA 2020
- Narrative synthesis (SWiM)
- Risk of bias assessed with JBI checklists and Murad tool
Pooled result
As reported in the abstract
Transition to central precocious puberty during follow-up
41.3%
Further pooled results
Girls with short stature without pubertal disorders
- One exploratory study evaluated this population
Safety
- Adverse events
- 3.3%
- No clinically significant hyperandrogenism or hepatotoxicity
Original publication
Letrozole in pediatric females for peripheral precocious puberty: a systematic review of efficacy and safety. J Clin Endocrinol Metab. Published 9 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →